Valion Bio Inc (VBIO) — Institutional Holders Breakdown (Q2 2026)

VBIO ranks #9446 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

VBIO is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

13 institutions disclose a position in VBIO, but none treat it as a major bet — even Murchinson Ltd., its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Marex Group Ltd has trimmed its VBIO position for two straight quarters, cutting it by $31.1K while still holding $28.2K.

VBIO reported a net loss of $18.8M over the trailing twelve months.

• Not yet profitable — net loss of $18.8M over the trailing twelve months
• Revenue declined 58.5% year over year
• Net income declined year over year, from -$6.3M to -$18.8M
• Operating cash flow was negative, using $7.0M in cash
• Current ratio of 20.13x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.44x equity — within a conventional range